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Other names: Par-4 (Prostate apoptosis gene 4); PAR4 
Location: 12q21.2 
Local order: Synaptotagmin I 12q21.2 on plus strand 
protein phosphatase 1, regulatory (inhibitor) subunit 
12A 12q21.2 on minus strand PAWR 12q21.2 on 
minus strand protein tyrosine phosphatase, receptor 
type, Q 12q21.2 on plus strand. 
DNA/RNA 
Description 
Genomic regions: Par-4/PAWR gene is encoded by the 
minus strand of chromosome 12q21.2. The gene 
encompasses 99.064 kb of DNA; 7 exons and 6 introns. 
ATG is located on exon 2. 
Transcription 





Human Par-4/PAWR is a about 40 kDa protein 
containing 340 amino acids. Rat Par-4 has 332 amino 
acids whereas mouse Par-4 has 333 amino acids. Par-
4/PAWR has two putative nuclear localization 
sequences in the N-terminal region and a leucine zipper 
domain and a nuclear export sequence in the C-terminal 
portion. There is a SAC domain (147-206 amino acids), 
selective for apoptosis induction in cancer cells. SAC 
domain is the effecter domain of Par-4/PAWR. These 
domains are 100% conserved in human, rat and mouse 
homologs. 
Expression 
Par-4/PAWR is ubiquitously expressed in normal 
mammalian tissues. However, Par-4/PAWR is 
diminished in a majority (>75% specimens) of renal 
cell carcinoma specimens. Par-4/PAWR expression is 
also decreased in endometrial tumors, neuroblastoma 
and in cells of patients with acute lymphatic leukemia 
and chronic lymphocytic leukemia. 
Localisation 
Immonocytochemical analysis indicates that Par-
4/PAWR is predominantly localized in cytoplasm in 
normal cells and is strongly localized in cytoplasm and 
nucleus in most cancer cell lines. However, Western 
blot analysis indicates that Par-4/PAWR is also in the 
nuclear fraction of normal cells implying it is masked 
in the nucleus. 
Function 
Par-4/PAWR, a pro-apoptotic protein, was first 
identified in prostate cancer cells that were induced to 
undergo apoptosis. Par-4 knockout mice spontaneously 
develop tumors of the liver, lung, and endometrium; 
prostatic intraepithelial neoplasia, and an increased 
frequency of estrogen-inducible tumors in the 
endometrium and BBN-inducible tumors in the 
bladder. Endogenous Par-4/PAWR expressed in normal 
and cancer cells does not, by itself, causes apoptosis, 
yet is essential for apoptosis via diverse cell death 
pathways. Par-4/PAWR sensitizes cells to apoptosis by 
wide variety of pro-apoptotic stimuli, such as growth 
factor withdrawal, agents that elevate intracellular C 2+, 
TNF, TRAIL, UV, X-ray and gamma irradiation, or 
IFN-gamma. Ectopic Par-4/PAWR over-expression is 
by itself sufficient to induce apoptosis in most can er 
cells, but not in normal or immortalized cells. The 
cancer selective pro-apoptotic function of Par-4/PAWR 
is localized in its central core SAC (Selective for 
Apoptosis-induction in Cancer cells) domain (amino 
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acids 147-206 in human Par-4/PAWR; or 137-195 in 
rat Par-4) which is 100% conserved in human, mouse 
and rat. Apoptosis by ectopic Par-4/PAWR requires 
Par-4/PAWR nuclear translocation and involves both 
activation of the Fas death receptor signaling pathw y 
and NF-kappaB inhibition. Par-4/PAWR also inhibits 
the prosurvival protein Bcl-2 and down regulates ERK-
2 expression. Neither p53 nor PTEN are directly 
required for apoptosis by Par-4/PAWR or the SAC 
domain. Par-4/PAWR has been shown to be involved 
in suppression of transformation by down-regulation of 
Ras. Overexpression of Par-4/PAWR results in 
apoptosis of cells expressing oncogenic Ras. 
Several partner proteins of Par-4/PAWR have been 
identified and partner interaction requires an intact Par-
4/PAWR leucine zipper domain. Par-4/PAWR 
associates with aPKC resulting in inhibition of NF-
kappaB activity, interaction with WT1 results in 
transcriptional repression of Bcl-2, whereas binding to 
and phosphorylation by Akt1 results in Par-4/PAWR 
cytoplasm retention by 14-3-3, thus isolating Par-
4/PAWR from its nuclear targets. Par-4/PAWR also 
binds to DLK/ZIP kinase (ZIPK) and induces 
DAAX/ZIPK-mediated apoptosis. In addition, THAP1 
(a novel nuclear pro-apoptotic factor) interacts with 
Par-4/PAWR and potentiates both serum withdrawal 
and TNF-induced apoptosis in endothelial cells. 
Par-4/PAWR is also involved in sensitization of 
neurons to apoptosis. Endogenous Par-4/PAWR is 
reported to be up-regulated in different 
neurodegenerative diseases including Alzheimer's, 
Huntington's and Parkinson's diseases and amyotrophic 
lateral sclerosis. 
Post-translational modifications: The apoptosis of Par-
4/PAWR requires phosphorylation of the threonine 
residue (T155 in rat Par-4/PAWR) in the SAC domain 
by PKA, which is elevated in cancer cells. Amino acid 
S249 in rat Par-4/PAWR is phosphorylated by AKT for 
Par-4/PAWR cytoplasm retention and inactivation. 
Homology 
The Par-4/PAWR gene has been identified in various 
organisms, including mammals (Pan troglodytes), 
rodents (mouse, rat), chicken (Gallus gallus), fish 
(Zebrafish and Pufferfish) and tadpole. The nuclear 
localization, leucine zipper, nuclear export and SAC 
domain sequences are highly conserved. 
Mutations 
Note: Par-4/PAWR mutations are uncommon although 
a single base mutation (Arg (CGA) 189 (TGA) Stop) 
localized in exon 3 or the SAC domain has been found 






Renal cell carcinoma and endometrial 
tumors 
Note: Par-4/PAWR is down regulated in over 75% of 
clear cell type of renal cell carcinoma, and in 
endometrial tumors. It is mutated within its effector 
SAC domain in endometrial tumors. 
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